Form 4: Corcept Therapeutics Executive Sells Shares After Exercising Options

A Corcept Therapeutics executive, Sean Maduck, sold 20,000 shares of common stock after exercising options, according to a recent SEC filing.

Summary

• Sean Maduck, President of Corcept Endocrinology, exercised options to acquire 20,000 shares of Corcept Therapeutics common stock at a price of $3.88 per share.
• Following the exercise of these options, Mr. Maduck sold the 20,000 shares at a price of $50.39 per share.
• After these transactions, Mr. Maduck directly owns 85,318 shares of Corcept Therapeutics common stock.
• Mr. Maduck also has indirect ownership of 10,000 shares through Duckhill Capital, LLC and 10,000 shares through the Sean and Molly Maduck Living Trust.
• The sale of shares was conducted under a pre-arranged 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing an executive's stock transactions. It is neutral in sentiment as it reflects routine activity.

Management Comments

• Sean Maduck is the President of Corcept Endocrinology.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan suggests the transaction was pre-planned and not based on any new material non-public information.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common occurrence in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
• The price difference between the exercise price and sale price is typical for stock options that have vested over time.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine insider sale.

Key Dates

Keywords

insider trading, stock options, SEC Form 4, share sale, Corcept Therapeutics, CORT, Sean Maduck